CoreCap Advisors’s Novavax NVAX Stock Holding History

CoreCap Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$465	Hold	43	–	–	﹤0.01%	2818
2026 Q2	$405	Hold	43	–	–	﹤0.01%	2906
2026 Q1	$350	Hold	43	–	–	﹤0.01%	2701
2025 Q4	$289	Sell	43 -100	-70%	-$754	﹤0.01%	2771
2025 Q3	$1.24K	Hold	143	–	–	﹤0.01%	2446
2025 Q2	$901	Hold	143	–	–	﹤0.01%	2438
2025 Q1	$917	Hold	143	–	–	﹤0.01%	2544
2024 Q4	$1.15K	Hold	143	–	–	﹤0.01%	2355
2024 Q3	$1.81K	Buy	+143	New	+$1.85K	﹤0.01%	2190
2024 Q2	–	Sell	-143	Closed	-$684	–	2271
2024 Q1	$684	Buy	+143	New	+$663	﹤0.01%	2288
2022 Q4	$1.47K	Buy	+143	New	+$2.52K	﹤0.01%	1995
2022 Q3	–	Sell	-153	Closed	-$8K	–	1551
2022 Q2	$8K	Buy	+153	New	+$7.92K	﹤0.01%	1540
2022 Q1	–	Sell	-536	Closed	-$77K	–	1544
2021 Q4	$77K	Buy	+536	New	+$92.1K	0.01%	857

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

CoreCap Advisors's NVAX Position: Q3 2026 in Review

CoreCap Advisors held its Novavax (NVAX) position steady in Q3 2026 at 43 shares worth $465. The position accounts for ﹤0.01% of the portfolio, ranked #2818.

CoreCap Advisors first reported a position in NVAX in Q4 2021 and has held it in 13 quarters since. The position peaked at $77K in Q4 2021. 5 funds tracked by Wall St. Rank hold NVAX as of Q3 2026.

CoreCap Advisors held 43 shares of Novavax worth $465 as of Q3 2026.
CoreCap Advisors left its Novavax share count unchanged in Q3 2026.
Novavax made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2818 holding.
CoreCap Advisors first reported a position in Novavax in Q4 2021 and has held it in 13 quarters since.
CoreCap Advisors's Novavax position peaked at $77K in Q4 2021.
5 funds tracked by Wall St. Rank held Novavax as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.